August 14, 2026 02:14 PM GMT Bristol Myers Squibb Co | North America What the Zenbexus approval means for CELMoDs in MM BMY's Zenbexus (Iberdomide; CELMoD) was approved on 8/13 in combination with JNJ's Darzalex Faspro and dex (Iber-Dd) for multiple myeloma (MM) patients with ≥1 prior line, including a proteasome inhibitor (PI) and IMiD (LINK). FDA approval was based on results from the Ph3 EXCALIBER-RRMM trial, where Iber-Dd achieved an MRD-negative CR rate of 41% vs. 21% for DVd (p<0.0001) at 16 months me ...